Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
Related Questions
Are recurrent UTIs a contraindication to SGLT2i use?
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
Do you recommend neuromodulation treatments with an implantable device for patients with chronic painful diabetic neuropathy who have not responded to common oral therapies such as Gabapentin and Amitriptyline?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Is there a role for using continuous glucose monitors for perioperative glucose monitoring in patients with diabetes?
Do you regularly counsel younger women of childbearing age about the impact of Tirzepatide on oral hormonal contraception?
Would you consider GLP1 R agonist therapy in a patient with a history of severe gallstone pancreatitis that is now post cholecystectomy?
Do you recommend the use of automated insulin delivery systems (such as Control IQ with Tandem insulin pumps) for managing gestational diabetes?
Is Metformin contraindicated in patients using long term oxygen therapy at home?
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
